Intervention: Elocon
Trial phase: Phase 3
ATC code: D07AC13 | D07XC03 | R01AD09 | R03AK09 | R03BA07
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(OC(=O)c1ccco1)C(=O)CCl
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 66
Group description: 1 spray (50 mcg) in each nostril twice daily (equivalent to 200 mcg per day) administered for 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
Eligibility criteria:
Inclusion Criteria:

Participants and their parents must demonstrate willingness to participate and comply with study procedures. Parents must sign a written informed consent
Participants and their parents must understand and be able to adhere to dosing and visit schedules, and agree to record symptom severity scores, medication times, and concomitant medications accurately and consistently in a daily diary
Children with a history of adenoid hypertrophy for at least 3 months with no response to previous medical treatment
Baseline adenoid tissue size must have been graded by nasopharyngoscopy examination as Grade III or IV on the Adenoid/Choana (A/C) Index (between 50% and 100% obstruction)
Baseline Total Severity Symptoms Score must be ≥ 8 points (AM or PM)
For inclusion in endpoints relating to otitis media with effusion (OME), participant must have persistent middle ear effusion for the past 3 months or more documented by otoscopic examination, middle ear pressure less than -150 mm H2O, Jerger type B flat tympanogram, and mild-moderate conductive hearing loss in audiometry supporting the diagnosis of OME

Exclusion Criteria:

Participants with previous surgery of hypertrophic adenoids with or without tympanostomy tube placement
Participants treated with inhaled or systemic corticosteroids within the past 1 month
Participants with Morbid Obesity (Body Mass Index >95 percentile of charts from the Centers for Disease Control)
Participants who have not accomplished the designated washout periods for any of the prohibited medications
Participants who have used any investigational products within the last 30 days
Participants who have used any antibodies for allergies in the past 90 days
Participants who have any abnormal physical examination results that may affect study evaluations or participant safety in the investigator's judgment
Participants who are allergic or have an idiosyncratic reaction to corticosteroids
Participants with signs and symptoms of acute or chronic bacterial rhinosinusitis
Participants has had an upper or lower respiratory tract or sinus infection that required antibiotic therapy with the last dose later than 14 days prior to screening, or who has had a viral upper or lower respiratory infection within 7 days prior to screening
Participants with a documented immunodeficiency condition
Participants with nasal structural abnormalities, including large nasal polyps and marked septum deviation that significantly interferes with nasal airflow
Participants with any clinically significant metabolic, cardiovascular, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disease (other than asthma), or any other disorder which, in the judgment of the Investigator, may interfere with the study evaluations or affect participant safety